These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29497019)

  • 1. A novel inhibitor stabilizes the inactive conformation of MAPK-interacting kinase 1.
    Matsui Y; Yasumatsu I; Yoshida KI; Iimura S; Ikeno Y; Nawano T; Fukano H; Ubukata O; Hanzawa H; Tanzawa F; Isoyama T
    Acta Crystallogr F Struct Biol Commun; 2018 Mar; 74(Pt 3):156-160. PubMed ID: 29497019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probing the binding mechanism of Mnk inhibitors by docking and molecular dynamics simulations.
    Kannan S; Poulsen A; Yang HY; Ho M; Ang SH; Eldwin TS; Jeyaraj DA; Chennamaneni LR; Liu B; Hill J; Verma CS; Nacro K
    Biochemistry; 2015 Jan; 54(1):32-46. PubMed ID: 25431995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal structures of the Mnk2 kinase domain reveal an inhibitory conformation and a zinc binding site.
    Jauch R; Jäkel S; Netter C; Schreiter K; Aicher B; Jäckle H; Wahl MC
    Structure; 2005 Oct; 13(10):1559-68. PubMed ID: 16216586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2.
    Waskiewicz AJ; Flynn A; Proud CG; Cooper JA
    EMBO J; 1997 Apr; 16(8):1909-20. PubMed ID: 9155017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 and MNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNK Inhibitors.
    Dreas A; Mikulski M; Milik M; Fabritius CH; Brzózka K; Rzymski T
    Curr Med Chem; 2017; 24(28):3025-3053. PubMed ID: 28164761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Mitogen-activated Protein Kinase (MAPK)-interacting Kinase (MNK) Preferentially Affects Translation of mRNAs Containing Both a 5'-Terminal Cap and Hairpin.
    Korneeva NL; Song A; Gram H; Edens MA; Rhoads RE
    J Biol Chem; 2016 Feb; 291(7):3455-67. PubMed ID: 26668315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of eukaryotic initiation factor 4E (eIF4E) phosphorylation by mitogen-activated protein kinase occurs through modulation of Mnk1-eIF4G interaction.
    Shveygert M; Kaiser C; Bradrick SS; Gromeier M
    Mol Cell Biol; 2010 Nov; 30(21):5160-7. PubMed ID: 20823271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Features of the catalytic domains and C termini of the MAPK signal-integrating kinases Mnk1 and Mnk2 determine their differing activities and regulatory properties.
    Parra JL; Buxadé M; Proud CG
    J Biol Chem; 2005 Nov; 280(45):37623-33. PubMed ID: 16162500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mitogen-activated protein kinase signal-integrating kinase Mnk2 is a eukaryotic initiation factor 4E kinase with high levels of basal activity in mammalian cells.
    Scheper GC; Morrice NA; Kleijn M; Proud CG
    Mol Cell Biol; 2001 Feb; 21(3):743-54. PubMed ID: 11154262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitogen-activated protein kinases interacting kinases are autoinhibited by a reprogrammed activation segment.
    Jauch R; Cho MK; Jäkel S; Netter C; Schreiter K; Aicher B; Zweckstetter M; Jäckle H; Wahl MC
    EMBO J; 2006 Sep; 25(17):4020-32. PubMed ID: 16917500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a Highly Conserved Allosteric Binding Site on Mnk1 and Mnk2.
    Basnet SK; Diab S; Schmid R; Yu M; Yang Y; Gillam TA; Teo T; Li P; Peat T; Albrecht H; Wang S
    Mol Pharmacol; 2015 Nov; 88(5):935-48. PubMed ID: 26268528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition.
    Reich SH; Sprengeler PA; Chiang GG; Appleman JR; Chen J; Clarine J; Eam B; Ernst JT; Han Q; Goel VK; Han EZR; Huang V; Hung INJ; Jemison A; Jessen KA; Molter J; Murphy D; Neal M; Parker GS; Shaghafi M; Sperry S; Staunton J; Stumpf CR; Thompson PA; Tran C; Webber SE; Wegerski CJ; Zheng H; Webster KR
    J Med Chem; 2018 Apr; 61(8):3516-3540. PubMed ID: 29526098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stepwise Evolution of Fragment Hits against MAPK Interacting Kinases 1 and 2.
    Kwiatkowski J; Liu B; Pang S; Ahmad NHB; Wang G; Poulsen A; Yang H; Poh YR; Tee DHY; Ong E; Retna P; Dinie N; Kwek P; Wee JLK; Manoharan V; Low CB; Seah PG; Pendharkar V; Sangthongpitag K; Joy J; Baburajendran N; Jansson AE; Nacro K; Hill J; Keller TH; Hung AW
    J Med Chem; 2020 Jan; 63(2):621-637. PubMed ID: 31910010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development.
    Ueda T; Watanabe-Fukunaga R; Fukuyama H; Nagata S; Fukunaga R
    Mol Cell Biol; 2004 Aug; 24(15):6539-49. PubMed ID: 15254222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MNK1 and MNK2 Expression in the Human Dorsal Root and Trigeminal Ganglion.
    Shiers S; Sahn JJ; Price TJ
    Neuroscience; 2023 Apr; 515():96-107. PubMed ID: 36764601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and activity of Mnk1 and Mnk2 selective inhibitors containing thieno[2,3-d]pyrimidine scaffold.
    Jin X; Merrett J; Tong S; Flower B; Xie J; Yu R; Tian S; Gao L; Zhao J; Wang X; Jiang T; Proud CG
    Eur J Med Chem; 2019 Jan; 162():735-751. PubMed ID: 30496989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel Mnk inhibitors using mutation-based induced-fit virtual high-throughput screening.
    Mishra RK; Clutter MR; Blyth GT; Kosciuczuk EM; Blackburn AZ; Beauchamp EM; Schiltz GE; Platanias LC
    Chem Biol Drug Des; 2019 Oct; 94(4):1813-1823. PubMed ID: 31260185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of pyridone-aminal derivatives as MNK1/2 inhibitors.
    Yuan X; Wu H; Bu H; Zheng P; Zhou J; Zhang H
    Bioorg Med Chem; 2019 Apr; 27(7):1211-1225. PubMed ID: 30824167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2.
    Dolniak B; Katsoulidis E; Carayol N; Altman JK; Redig AJ; Tallman MS; Ueda T; Watanabe-Fukunaga R; Fukunaga R; Platanias LC
    J Biol Chem; 2008 May; 283(18):12034-42. PubMed ID: 18299328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on the Development of MNK Inhibitors as Therapeutic Agents.
    Xu W; Kannan S; Verma CS; Nacro K
    J Med Chem; 2022 Jan; 65(2):983-1007. PubMed ID: 34533957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.